• Imatinib was first approved for

  2023-02-06

  

  Imatinib was first approved for the treatment of Philadelphia chromosome positive chronic myelogenous leukemia in 2001 [25]. This first approved small molecule antagonist is quite unusual in that it provides a durable response that lasts for more than a decade in the majority of patients. Imatinib h

• In addition to it we

  2023-02-06

  

  In addition to it, we also showed that glycine increases miR-301a expression which directly binds to PTEN 3′UTR target sites [13]. Glycine confers neuroprotection through microRNA-301a/PTEN signaling in rats cortical neurons in oxygen deprivation model [13]. Substantial studies indicate that inhibit

• chloroquine phosphate br Conflict of interest statement br A

  2023-02-06

  

  Conflict of interest statement Acknowledgements We are very grateful to Maura Agate for her excellent editorial assistance. The work reported in this article was supported largely by the Italian MIUR. Introduction Atenolol is a selective β1-adrenergic receptor blocker that is orally effect

• br Discussion With recently improved understanding of the ro

  2023-02-06

  

  Discussion With recently improved understanding of the role of βARK1 in the progression of HF and as a potential therapeutic target in HF, we explored the relationship between plasma βARK1, as a marker of chronic sympathetic overactivation, and physical symptoms in HF. Our main findings were 1) e

• Subsequently Palvimaki et al corroborated Ni and Miledi s

  2023-02-06

  

  Subsequently, Palvimaki et al. (1999) corroborated Ni and Miledi's study by demonstrating that treatment with fluoxetine leads to 43% occupancy of the 5-HT2C receptors. Moreover, the affinity of fluoxetine for 5HT2C receptors (Ki 65 nM) is close to its affinity for 5-HT transporters (Ki 33 nM) (Ni a

• ACK can be localized to

  2023-02-03

  

  ACK1 can be localized to clathrin-coated vesicles [1]. The association of SNX9 with synaptojanin-1 would suggest the two cooperate during endocytosis at the synapse by coupling the sorting nexin to changes in phospholipid composition. ACK1 in turn negatively regulates the association of SNX9 with ta

• Crohn s disease an inflammatory bowel disease that

  2023-02-01

  

  Crohn’s disease, an inflammatory bowel disease that affects the gastrointestinal (GI) tract, is characterized by a polymorphism in ULK1 autophagy gene due to the presence of single nucleotide polymorphisms (SNPs). Thus, the autophagic process is impaired during the disease. The mutations in the leuc

• br Results br Discussion ER

  2023-02-01

  

  Results Discussion ER and GR play opposite phenotypic roles in the normal endometrium, with ER promoting growth and GR inhibiting growth. Here, we show that in endometrial cancer, GR expression is associated with worse outcomes and higher-grade tumors, and this association is observed only in

• br Acknowledgments and Disclosures br Introduction Over the

  2023-02-01

  

  Acknowledgments and Disclosures Introduction Over the last decade, the most visible strategy for the treatment of Alzheimer's disease (AD) has been amyloid β peptide (Aβ) immunotherapy (reviewed in [1]). Although the first efforts with Aβ immunotherapy failed to complete clinical trials [1], A

• br Conflicts of interest br Funding

  2023-02-01

  

  Conflicts of interest Funding Introduction Brassicaceae is an economically important family of plants containing rapeseed, cabbage, broccoli, brussels, radish and mustard. Among them rapeseed plays a crucial role, because of its application in food and also in fuel industry. According to th

• We next developed a system for staging severity Our

  2023-02-01

  

  We next developed a system for staging severity. Our guiding principles were the following. Two types of information about the research participant are staged independently from each other: (1) grading disease severity using biomarkers and (2) grading the severity of cognitive impairment. Measures u

• br Potential and established risk factor for Alzheimer

  2023-02-01

  

  Potential and established risk factor for Alzheimer’s Disease The only way to overcome the above mentioned limitations is the identification of risk factors, which, taken together, can reliable predict the development of AD. Age and ApoE4 are established non-modifiable risk factors for AD. The ri

• An important observation is that this patient has been on

  2023-02-01

  

  An important observation is that this patient has been on ALK inhibitor for more than 4 years (51 months: 27 months on crizotinib+24 months on alectinib and on-going) and there was no evidence of disease progression in the central nervous system. The other potential driver mutation in this patient’s

• Previous studies to investigate the functions of

  2023-02-01

  

  Previous studies to investigate the functions of AHR in Treg GSK1016790A sale have employed a loss-of-function approach, using AHR complete-null mice, or a gain-of-function approach by ligand administration. However, these approaches may confound the interpretation of the results. For example, the

• br LO and the secretase complex Supporting this concept

  2023-02-01

  

  5LO and the γ-secretase complex Supporting this concept, during a recent trial testing the γ-secretase inhibitor semagacestat (LY 450139), AD patients actually experienced a functional decline compared to patients who took a placebo in addition to several other significant adverse effects (Doody

15195 records 282/1013 page Previous Next First page 上5页 281282283284285 下5页 Last page